← Back to headlines
Amgen and AstraZeneca Drug Combo Shows Promise in Lung Cancer Trial
A combination therapy involving drugs from Amgen and AstraZeneca has been shown to extend survival rates in late-stage clinical trials for lung cancer patients.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
